At the early stage, Grail, a developer of diagnostics for early cancer detection, closed a $1.2 billion Series B round, the largest early-stage deal for Q4.
MJL, HPO, and GJF are current employees of AmberGen, Inc., a developer of commercial diagnostic assays.
RSR Ltd is a developer of medical diagnostics including kits for measuring TSH receptor autoantibodies.
The most amazing comeback is that of Vermillion, a tiny developer of diagnostic tests that is still in Chapter 11 bankruptcy.
So could GRAIL, which has raised $1.3 billionn for cancer diagnostics; Evelo Biosciences, a developer of therapies based on the human microbiome, and others.
Among those companies are Mushroom Networks, a developer of online video technology, and, more recently, Biological Dynamics, a maker of early cancer diagnostic technology.
Ventana Medical Systems, which makes cancer diagnostic equipment, is expected to announce today that it will acquire Spring Bioscience, a developer of antibodies, for $28.9 million in cash as it continues to battle a hostile takeover offer from the Swiss drug maker Roche Holding.
Spatialight is a developer of LCOS chips for RPTVs.
It has even become a developer of Web gadgets.
NeoGenesis is a developer of small molecule drugs.
